Stephanie L Graff, Christine McGinn, Jeanine R Showalter
{"title":"改善转移性 HER2 阳性和 HER2 阴性乳腺癌女性患者的治疗效果。","authors":"Stephanie L Graff, Christine McGinn, Jeanine R Showalter","doi":"10.6004/jadpro.2024.15.3.6","DOIUrl":null,"url":null,"abstract":"<p><p>At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status, and evidence-based practices for managing adverse events associated with novel HER2 agents.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 3","pages":"187-190"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406316/pdf/","citationCount":"0","resultStr":"{\"title\":\"Improving Outcomes for Women With Metastatic HER<sub>2</sub>-Positive and HER<sub>2</sub>-Low Breast Cancer.\",\"authors\":\"Stephanie L Graff, Christine McGinn, Jeanine R Showalter\",\"doi\":\"10.6004/jadpro.2024.15.3.6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status, and evidence-based practices for managing adverse events associated with novel HER2 agents.</p>\",\"PeriodicalId\":94110,\"journal\":{\"name\":\"Journal of the advanced practitioner in oncology\",\"volume\":\"15 3\",\"pages\":\"187-190\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406316/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the advanced practitioner in oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2024.15.3.6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the advanced practitioner in oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2024.15.3.6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在 JADPRO Live 2023 上，发言人讨论了转移性 HER2 阳性转移性乳腺癌临床实践的最新进展。会议期间，他们回顾了FDA最近的批准情况、HER2-low状态的临床相关性以及管理新型HER2药物相关不良事件的循证实践。
Improving Outcomes for Women With Metastatic HER2-Positive and HER2-Low Breast Cancer.
At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status, and evidence-based practices for managing adverse events associated with novel HER2 agents.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
